TEM
Tempus AI, Inc.
October 6, 2026 · intraday
- Rarity
- 1.74
- Peak move
- −14.13%
- Float cap
- $8.7B
Tempus AI is a healthcare technology company that provides AI-enabled diagnostics, including next-generation sequencing, PCR profiling, and anatomic and molecular pathology testing, to healthcare providers, life sciences companies, researchers, and other third parties. It also offers data and applications products that license de-identified clinical, molecular, and imaging data and provide analytics and clinical trial support to pharmaceutical and biotechnology companies.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
6 events · 0 from SEC or newswire · 1 timed with the move- Timed with the move
analyst_ratingBTIG downgraded Personalis to Neutral from Buy, citing confidence that Tempus AI's roughly $1.5 billion acquisition of Personalis will close on announced terms in the coming months.
analyst_ratingA FactSet survey of 18 analysts raised the median price target on Tempus AI Class A to $74 from $71.50, a 3.5% increase, with estimates ranging from $35 to $100 and 23 analysts split 10 bullish, 11 neutral and 2 bearish.
acquisition_acquirerTempus AI filed a pre-effective amendment to its Form S-4 registration statement for its pending acquisition of Personalis under the July 20, 2026 merger agreement, setting a Personalis special meeting to vote on the deal.
analyst_ratingGuggenheim analyst Subbu Nambi raised the price target on Tempus AI to $92 from $65 while keeping a Buy rating, updating valuation models ahead of Q3 earnings.
regulatory_approvalTempus AI received FDA 510(k) clearance for Tempus ECG-MR, an AI software analyzing resting 12-lead ECGs to flag undiagnosed moderate or severe mitral regurgitation in patients 65 and older, its fourth FDA-cleared ECG-AI product.
peer_disclosureTempus AI and Recursion Pharmaceuticals extended their data license agreement through November 2029, replacing discretionary fees potentially totaling $84 million over two years with committed payments of $42 million over three years, and Tempus licensed Recursion's TxFM RNA foundation model for $12 million over two years.